"2020 POST ASCO" Seminar on the Latest Progress in Lymphoma successfully concluded!

Entering the vigorous July, we ushered in the annual post ASCO.on July 5, 2020, the "2020 post ASCO" sponsored by the Affiliated Cancer Hospital of Harbin Medical University officially opened.communicate with you in the form of expert online lectures and discussions.24 authoritative experts in lymphoma from many places in China gathered in the live studio to share the achievements in lymphoma field at ASCO 2020 meeting, and discuss and share experience on difficult problems.the conference invited Professor Zhang Qingyuan, Affiliated Tumor Hospital of Harbin Medical University, as the chairman of the conference.professors Zhou Jianfeng from Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology, Professor Xue Hongwei, Affiliated Hospital of Qingdao University, Professor Su Liping of Cancer Hospital Affiliated to Shanxi Medical University, Professor Zhou Hui of Hunan cancer hospital / Affiliated Tumor Hospital of Xiangya Medical College of Central South University, and Professor Liu Lihong of the fourth hospital of Hebei Medical University / Hebei cancer hospital Professor Zhang Qingyuan, Cancer Hospital Affiliated to Harbin Medical University.the opening ceremony of the conference was delivered by Professor Zhang Qingyuan.first of all, Professor Zhang extended a warm welcome to our colleagues in the field of lymphoma and solid tumors.in his speech, Professor Zhang said that lymphoma has developed rapidly in recent years, and new research, new hot spots, new ideas and new drugs of ASCO emerge in endlessly every year, which requires our continuous study and analysis.it is of positive significance to master the progress of ASCO annual meeting. By refining the progress of ASCO in the field of lymphoma by domestic speakers, we can better learn and master the huge amount of frontier information in ASCO meeting, and further promote the level of lymphoma diagnosis and treatment in China.at the same time, Professor Zhang wishes the conference a complete success.topic 1: the latest progress of car-t cell therapy, Professor Zhou Jianfeng, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of science and technology, delivered a keynote speech on "car-t cell immunotherapy for blood tumors: current situation and challenges".Professor Zhou gave a comprehensive and detailed explanation on the research and development status of car-t in China, the transformation of research mode in the field of car-t in China and the bottleneck problems to be solved in China car-t industry.at the same time, Professor Zhou said that the breakthrough of car-t development is based on the accumulation of more than 20 years. China's car-t research has gradually formed some representative teams. Some car-t with independent intellectual property rights in China is going to the international market, and the research mode driven by industrialization is forming in China's car-t field.finally, Professor Zhou pointed out that China's car-t industry needs to focus on the solution of bottleneck problems (such as the high manufacturing cost and lack of universality in GMP environment; the side effects and safety of car-t; the high-throughput screening platform of original car-t, etc.).under the chairmanship of Professor Bai ou, Professor Zhou discussed with the guest guests Professor Leng Qing, Professor Cui Xinyu and online experts on whether to use PD-1 immunotherapy, how long PD-1 treatment can be maintained, whether combined with lenalidomide, and the timing of autologous transplantation.topic 2: progress in the treatment of chronic lymphoblastic leukemia (CLL), Professor Xue Hongwei, Affiliated Hospital of Qingdao University, presented a speech on the theme of "CLL diagnosis and treatment 2020, CLL focus issues and new progress". Professor Xue made a detailed exposition on the five focuses, such as clone evolution model, prognosis system, diagnosis and differential concerns, treatment timing and thinking brought by new clinical research (ASCO ESH). under the chairmanship of Professor Zou Liqun, the guest of discussion, Professor Zhao Donglu, said that CLL has changed from traditional single drug treatment to combined treatment and non chemotherapy combination. Due to the epidemic situation, patients' choice of treatment drugs for CLL is also quietly changing. guest of discussion, Professor Zhang Chun shared with you the treatment opportunity and clinical treatment experience of CLL. topic 3: progress in the treatment of diffuse large B-cell lymphoma (DLBCL), Professor Su Liping, Affiliated Cancer Hospital of Shanxi Medical University, presented a wonderful keynote speech entitled "progress in the treatment of refractory / relapsed diffuse large B-cell lymphoma (R / R DLBCL) - focus on ASCO / EHA". Professor Su first summarized the current situation of R / R DLBCL treatment and the choice of treatment path, and then focused on 2020 ASCO and EHA to elaborate the traditional improved chemotherapy scheme of R / R DLBCL, the combination of existing small molecule drugs and the clinical application of new targeted drugs. finally, Professor Su concluded that the prognosis of R / R DLBCL was poor, and ASCT and car-t were still the main choices. for patients with primary drug resistance and / or refractory, the combination of traditional chemotherapy regimens may still be a choice for R / R DLBCL; for primary drug resistance, refractory and high-grade B, the combination of small molecule drugs has a good prospect; for highly refractory and resistant DLBCL, new targeted drugs may be the hope of bottleneck breakthrough. under the chairmanship of Professor Li Xiaoling, Professor Su discussed the multi-dimensional treatment of B-cell lymphoma, including second-line treatment, autologous transplantation, car-t, and whether chemotherapy combined with immunotherapy can be implemented in lymphadenoma. topic 4: treatment progress of T-cell lymphoma Professor Zhou Hui from Hunan cancer hospital / Affiliated Cancer Hospital of Xiangya Medical College of Central South University gave a keynote speech on "progress in diagnosis and treatment of peripheral T-cell lymphoma (PTCL)". Professor Zhang first introduced the general situation of PTCL. then, the pathological classification and diagnosis and treatment progress of DLBCL were elaborated in detail. finally, Professor Zhang concluded that PTCL has a poor prognosis, and the commonly used chop or chop like regimen has poor efficacy; ASCT has a tendency to benefit, and it is a trend to introduce new drugs in the initial treatment / relapse and refractory treatment, which is expected to improve the prognosis of patients. with the deepening understanding of signaling pathways and therapeutic targets, it is believed that comprehensive and individualized treatment with novel biological targeting drugs combined with existing effective schemes will help to improve the therapeutic effect and clinical prognosis of PTCL. under the chairmanship of Professor Bai Yuansong, Professor Zhou had a heated discussion with the discussion guests, Professor Zhao Shu and Professor Liao Aijun, on the first-line treatment (such as the choice and timing of stem cell transplantation: autologous transplantation and allogeneic transplantation), immunotherapy, how to choose gene test in clinical practice, and the treatment of refractory relapse. topic 5: progress in the treatment of follicular lymphoma Professor Liu Lihong from the fourth hospital of Hebei Medical University / Hebei Cancer Hospital presented a keynote speech on "research progress of follicular lymphoma (FL)". Professor Liu first introduced the disease overview of follicular lymphoma, and then elaborated the research progress of ASCO and EHA follicular lymphoma. finally, Professor Liu concluded that in the future, different prognosis evaluation systems and tumor microenvironment factors are needed for different treatment regimens in fl. in terms of radiotherapy, the combination of immunotherapy and radiotherapy can improve the prognosis of patients; MRD detected by PCR can not screen out patients who do not need immunotherapy. in terms of immunotherapy, CD20 monoclonal antibody combined with lenalidomide is effective in the initial treatment and R / R FL, which brings more hope for FL without chemotherapy; small molecule drugs and bispecific antibody drugs also bring new choices for FL treatment. under the chairmanship of Professor Wang Yalan, Professor Liu had a heated discussion with the discussion guests, Professor Li Xiaoxia and Professor Xu Jihong on the characteristics of FL patients, such as age, no chemotherapy regimen, complications, transplantation, and clinical special cases. topic 6: progress in the treatment of mantle cell lymphoma Professor Zhang Qingyuan, Affiliated Tumor Hospital of Harbin Medical University, presented a wonderful keynote speech on "progress in the treatment of mantle cell lymphoma (MCL)". Professor Zhang respectively elaborated the disease overview of MCL, the treatment progress of newly diagnosed MCL and relapsed / refractory MCL. finally, Professor Zhang concluded that the overall prognosis of MCL is poor. According to the prognostic factors, age, and concomitant diseases, it is decided whether intensive chemotherapy + ASCT or mild treatment is suitable; Btk inhibitors, bcl-2 inhibitors, immunotherapy drugs and other targeted drugs significantly improve the effect of MCL, and also bring new options without chemotherapy for patients with MCL who can not tolerate chemotherapy; in other areas, the use of BTK inhibitors, bcl-2 inhibitors and immunotherapy drugs can significantly improve the effect of MCL Small molecule inhibitors have also seen certain effect, and the future research direction will be high-efficiency + low toxicity treatment and targeted therapy combination. under the chairmanship of Professor Wang Ye, Professor Zhang had a positive and warm discussion with the guest guests Professor Wang Wei and Professor Bi Lintao on the special cases in clinical practice, maintenance treatment of MCL, and TP53 gene mutation therapy. at the end of the meeting, the chairman of the meeting, Professor Zhang Qingyuan, made a concluding speech on the meeting. Professor Zhang once again expressed his thanks for your support and wonderful report, so that colleagues in lymphoma field can learn the latest international progress in time and provide better treatment for domestic patients. in addition, the special salon on extranodal lymphoma will be held once a month from August to December, and we look forward to your attention and participation. to this end, the 2020 post ASCO lymphoma Update seminar was successfully concluded. stamp "read the original text", and let's make progress together